Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 79
Filtrar
Mais filtros

Medicinas Complementares
Tipo de documento
Intervalo de ano de publicação
1.
J Postgrad Med ; 67(1): 36-38, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33533750

RESUMO

Glyphosate is the most commonly used broad-spectrum, non-selective herbicide in the world. The toxicity is supposed to be due to uncoupling of oxidative phosphorylation and the surfactant polyoxyethylene amine (POEA)- mediated cardiotoxicity. Clinical features of this herbicide poisoning are varied, ranging from asymptomatic to even death. There is no antidote and aggressive supportive therapy is the mainstay of treatment for glyphosate poisoning. We present a 69-year-old female patient with suicidal consumption of around 500 ml of Glycel®. Initially, gastric lavage was done and intravenous fluids were given. Within two hours of presentation, the patient developed respiratory distress needing intubation, hypotension needing vasopressor support, and severe lactic acidosis. She also developed acute respiratory distress syndrome, hypokalemia, hypernatremia, and aspiration pneumonia. Our patient was critically ill with multiple poor prognostic factors, but with timely aggressive supportive management, the patient gradually recovered.


Assuntos
Glicina/análogos & derivados , Herbicidas/intoxicação , Hipernatremia/etiologia , Hipopotassemia/etiologia , Pneumonia Aspirativa/etiologia , Síndrome do Desconforto Respiratório/etiologia , Idoso , Cefamandol/administração & dosagem , Cefamandol/análogos & derivados , Cefamandol/uso terapêutico , Cefoperazona/administração & dosagem , Cefoperazona/uso terapêutico , Clindamicina/administração & dosagem , Clindamicina/uso terapêutico , Suplementos Nutricionais , Feminino , Glicina/intoxicação , Humanos , Hipernatremia/tratamento farmacológico , Hipopotassemia/tratamento farmacológico , Pneumonia Aspirativa/tratamento farmacológico , Potássio/administração & dosagem , Potássio/uso terapêutico , Síndrome do Desconforto Respiratório/tratamento farmacológico , Tentativa de Suicídio , Sulbactam/administração & dosagem , Sulbactam/uso terapêutico , Resultado do Tratamento , Glifosato
2.
G Ital Dermatol Venereol ; 155(6): 749-753, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30249083

RESUMO

BACKGROUND: Over recent years, the link between obesity, metabolic syndrome and Hidradenitis suppurativa (HS) has been explored. It has been demonstrated that HS patients have a high prevalence of the metabolic syndrome and an increased frequency of insulin resistance. The objective of our study is to estimate the effectiveness of an oral supplementation based on myo-inositol (MI), folic acid and liposomal magnesium (Levigon®, Sanitpharma; Milan, Italy) on the clinical and metabolic profile of patients affected by HS. METHODS: Twenty subjects with HS and an impaired glucose metabolism were enrolled. Group A: 10 subjects received for 6 months MI 2000 mg, liposomal magnesium and folic acid associated to topical antibiotic therapy (clindamycin gel 1%), systemic antibiotic therapy (clindamycin 300 mg b.i.d. and rifampicin 600 mg daily for 6 weeks) and a normocaloric diet group B: 10 subjects received topical and systemic antibiotic therapy associated to a normocaloric diet for 6 months. RESULTS: After 6 months group A patients showed an average reduction of Sartorius Score from 38.3±7.75 to 27.3±13.53 (P value <0.04) while in the control group there was a reduction of the Sartorius from 38.4±7.88 to 31.1±8.02 (P value =0.55). Moreover in group A Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was significantly reduced from 2.43±0.35 to 2.1±0.31 (P<0.01) whereas in group B HOMA-IR did not significantly decrease (2.51±0.65 at T0 at 2.40±0.67 at T1). CONCLUSIONS: Our study underlines the importance of the evaluation of metabolic profile in patients with HS. Moreover, it suggests that the supplementation of MI, folic acid and liposomal magnesium in HS can improve the efficacy of concomitant therapies and the metabolic profile.


Assuntos
Suplementos Nutricionais , Intolerância à Glucose/complicações , Hidradenite Supurativa/tratamento farmacológico , Administração Cutânea , Administração Oral , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Clindamicina/administração & dosagem , Clindamicina/uso terapêutico , Combinação de Medicamentos , Quimioterapia Combinada , Ingestão de Energia , Ácido Fólico/administração & dosagem , Ácido Fólico/uso terapêutico , Intolerância à Glucose/dietoterapia , Hidradenite Supurativa/complicações , Hidradenite Supurativa/epidemiologia , Hidradenite Supurativa/metabolismo , Humanos , Inositol/administração & dosagem , Inositol/uso terapêutico , Resistência à Insulina , Lipossomos , Magnésio/administração & dosagem , Magnésio/uso terapêutico , Síndrome Metabólica/complicações , Síndrome Metabólica/dietoterapia , Prevalência , Rifampina/administração & dosagem , Rifampina/uso terapêutico , Índice de Gravidade de Doença
4.
Phytother Res ; 31(3): 410-417, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28124400

RESUMO

Acne vulgaris, a chronic condition associated with overgrowth of Propionibacterium acnes and Staphylococcus epidermidis, is commonly treated with antibiotics. However, the emergence of antibiotic resistance has resulted in a need for alternative therapies. The aim of this study is to develop a topical preparation incorporating essential oils (EOs) for use against acne-associated bacteria and assess its efficacy against prescription therapies Dalacin T and Stiemycin. Antimicrobial screening of rosewood, clove bud and litsea EOs was conducted before interactions between binary and ternary combinations were determined against P. acnes and S. epidermidis (type and clinical isolates) using minimum inhibitory concentrations and fractional inhibitory concentrations. The EOs were characterised by both gas chromatography-mass spectrometry and nuclear magnetic resonance. A combination of 0.53 mg/mL litsea, 0.11 mg/mL rosewood and 0.11 mg/mL clove bud was formulated into herbal distillates and compared with Dalacin T and Stiemycin against antibiotic sensitive and resistant isolates (erythromycin). The distillate with EO had synergistic activity against P. acnes (7log10 reduction) and indifferent activity against S. epidermidis (6log10 reduction); antimicrobial activity was either significantly (p ≤ 0.05) more antimicrobial or equivalent to that of Dalacin T and Stiemycin. This formulation may serve as a valuable alternative for the control of acne vulgaris-associated bacteria. Copyright © 2017 John Wiley & Sons, Ltd.


Assuntos
Acne Vulgar/microbiologia , Antibacterianos/administração & dosagem , Óleos Voláteis/administração & dosagem , Óleos Voláteis/farmacologia , Propionibacterium acnes/efeitos dos fármacos , Staphylococcus epidermidis/efeitos dos fármacos , Acne Vulgar/tratamento farmacológico , Administração Tópica , Antibacterianos/farmacologia , Anti-Infecciosos/administração & dosagem , Clindamicina/administração & dosagem , Clindamicina/farmacologia , Combinação de Medicamentos , Sinergismo Farmacológico , Eritromicina/administração & dosagem , Eritromicina/farmacologia , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Testes de Sensibilidade Microbiana , Óleos Voláteis/química , Propionibacterium acnes/crescimento & desenvolvimento , Staphylococcus epidermidis/crescimento & desenvolvimento
5.
J Med Assoc Thai ; 100(1): 78-85, 2017 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29911775

RESUMO

Background: Treatments of acne vulgaris commonly use antimicrobials and comedolytic agents. Considering bacterial resistance to topical antibiotics, the alternative treatment such as silver manufactured into nanoparticle receives an attention. Silver nanoparticle has an antibacterial effect against Propionibacterium acnes and anti-inflammation. Clinical study of silver nanoparticle gel for the treatment of acne vulgaris is limited. Objective: To compare the efficacy and safety between silver nanoparticle gel and 1% clindamycin gel both combine with 2.5% benzoyl peroxide for the treatment of moderate severity of acne vulgaris. Material and Method: This was an experimental, double-blinded, randomized-controlled study. Sixty-four moderately severe acne patients were enrolled. They were randomized to receive either silver nanoparticle gel with 2.5% benzoyl peroxide or clindamycin gel with 2.5% benzoyl peroxide (32 patients each). The clinical outcomes were evaluated for inflammatory and non-inflammatory acne count, acne redness, the patients' satisfaction and patients' Dermatology Life Quality Index (DLQI) at the baseline, 2, 4, 6 and 8-week visit. Results: After 8 weeks of follow-up period, the average mean percent change from the baseline of non-inflammatory and inflammatory acne counts were gradually declined in both silver nanoparticle and clindamycin group. At the study endpoint (8-week visit), average mean percent change from the baseline of inflammatory acne count was slightly better reduction in silver nanoparticle group (79.7%) than clindamycin group (72.6%) with no significant difference (p = 0.18). The average mean percent change from the baseline of non-inflammatory acne count reduction was also no difference from silver nanoparticle and clindamycin group (61.1% and 66.8% respectively, p = 0.22). For clinical erythema score and Mexameter erythema index to evaluate acne redness were no statistical difference between the 2 groups. Moreover, the patients' satisfaction to study medication and their quality of life of patients (DLQI score) were reported with better improvement from the baseline in both groups but there was no statistical significant difference. Except for average mean, patients' satisfaction to acne severity at 6-week visit showed that silver nanoparticle group had better satisfaction score than clindamycin group (4.6±0.6 vs. 4.2±0.6) with statistical significance (p = 0.01). Common adverse effects were skin dryness (28.1%) and skin irritation (4.7%) which might be caused by 2.5% benzoyl peroxide. There was no adverse effect for silver nanoparticle gel from the present study. Conclusion: Silver nanoparticle gel is effective with good safety profile for the treatment of acne vulgaris. The present study demonstrated that there were no clinical significant differences between silver nanoparticle gel and clindamycin gel for the treatment of moderate severity of acne vulgaris when use in combination with 2.5% benzoyl peroxide. The clinical application as alternative treatment for acne is advised.


Assuntos
Acne Vulgar/tratamento farmacológico , Antibacterianos/uso terapêutico , Peróxido de Benzoíla/uso terapêutico , Clindamicina/uso terapêutico , Nanopartículas Metálicas/uso terapêutico , Adulto , Antibacterianos/administração & dosagem , Clindamicina/administração & dosagem , Método Duplo-Cego , Quimioterapia Combinada/métodos , Feminino , Seguimentos , Géis , Humanos , Masculino , Satisfação do Paciente , Qualidade de Vida , Prata/uso terapêutico , Resultado do Tratamento , Adulto Jovem
6.
J Infect Dev Ctries ; 10(11): 1208-1213, 2016 Nov 24.
Artigo em Inglês | MEDLINE | ID: mdl-27886033

RESUMO

INTRODUCTION: The use of bacteriophages as an alternative treatment method against multidrug-resistant bacteria has not been explored in Kenya. This study sought to determine the efficacy of environmentally obtained lytic bacteriophage against multidrug-resistant Staphylococcus aureus (MDRSA) bacterium in mice. METHODOLOGY: Staphylococcus aureus bacterium and S. aureus-specific lytic phage were isolated from sewage and wastewater collected within Nairobi County, Kenya. Thirty mice were randomly assigned into three groups: MDRSA infection group (n = 20), phage-infection group (n = 5), and non-infection group (n = 5). The MDRSA infection group was further subdivided into three groups: clindamycin treatment (8 mg/kg; n = 5), lytic phage treatment (108 PFU/mL (n = 5), and a combination treatment of clindamycin and lytic phage (n = 5). Treatments were done at either 24 or 72 hours post-infection (p.i), and data on efficacy, bacterial load, and animal physical health were collected. RESULTS: Treatment with phage was more effective (100%) than with clindamycin (62.25% at 24 hours p.i and 87.5% at 72 hours p.i.) or combination treatment (75% at 24 hours p.i. and 90% at 72 hours p.i.) (p < 0.001). CONCLUSIONS: The results show that the environmentally obtained S. aureus lytic bacteriophage has therapeutic potential against MDRSA bacterium in mice.


Assuntos
Terapia Biológica/métodos , Infecções Estafilocócicas/terapia , Fagos de Staphylococcus/crescimento & desenvolvimento , Staphylococcus aureus/virologia , Animais , Antibacterianos/administração & dosagem , Carga Bacteriana , Clindamicina/administração & dosagem , Terapia Combinada , Modelos Animais de Doenças , Farmacorresistência Bacteriana Múltipla , Feminino , Quênia , Masculino , Camundongos Endogâmicos BALB C , Infecções Estafilocócicas/patologia , Fagos de Staphylococcus/isolamento & purificação , Staphylococcus aureus/efeitos dos fármacos , Staphylococcus aureus/isolamento & purificação , Análise de Sobrevida , Resultado do Tratamento , Carga Viral , Águas Residuárias/microbiologia , Águas Residuárias/virologia
7.
Br J Neurosurg ; 30(5): 560-6, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27195449

RESUMO

BACKGROUND: The introduction of antibiotic-impregnated catheters (AICs) has significantly reduced external ventricular drain (EVD) infection rates, inhibiting in particular Gram-positive microbial infection. There is a theoretical increased risk of selection of resistant and Gram-negative microorganisms. The aim of this study is to look at the impact of the introduction of AICs on microorganism susceptibility of infected EVDs and to determine whether the use of such devices results in shift from Gram-positive to Gram-negative microorganisms. A secondary aim is to determine if a change in routine empiric antimicrobial therapy is required because of a change in the microorganism(s) causing infection. METHODS: Retrospective analysis of EVDs inserted as a primary procedure or part of a concomitant neurosurgical procedure in 2006 (pre-AIC) and 2012 (post-AIC Codman Bactiseal(©) impregnated with clindamycin 0.15% and rifampicin 0.054%). EVD-related infection was defined as a cerebral spinal fluid sample with a positive culture with some patients having one or more microorganisms infecting the same EVD at the same time. Sixty-five EVDs over 843 days and 66 EVDs over 619 days were inserted respectively in each cohort. RESULTS: In 2006, 9 of 35 patients developed EVD-related infection and 13 microorganisms were cultured; 8 of which were Gram-positive and 4 Gram-negative. Four of 49 patients developed EVD-related infection in 2012 and six microorganisms were cultured; four Gram-positive and two Gram-negative. The cumulative incidence of EVDs becoming infected is 18.5% (12/65) and 6.1% (4/66; p = 0.03) in 2012. The EVD-associated infection rate was 14.2 per 1000 EVD days and 6.5 per 1000 EVD days in 2012. There was no change in mortality. CONCLUSIONS: The study demonstrates that within a single neurosurgical centre there have been neither changes in susceptibility of microorganisms nor a change from predominately Gram-positive to Gram-negative microorganisms infecting EVDs following the switch to AIC. The infection rate has significantly reduced due to change in catheter type.


Assuntos
Antibacterianos/uso terapêutico , Infecções Relacionadas a Cateter/epidemiologia , Infecções Relacionadas a Cateter/prevenção & controle , Catéteres , Ventrículos Cerebrais , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/administração & dosagem , Infecções Relacionadas a Cateter/microbiologia , Clindamicina/administração & dosagem , Clindamicina/uso terapêutico , Drenagem , Feminino , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Humanos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Neurocirurgia , Estudos Retrospectivos , Rifampina/administração & dosagem , Rifampina/uso terapêutico , Adulto Jovem
8.
Pediatr Dermatol ; 32(5): 579-92, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25816855

RESUMO

Pityriasis lichenoides (PL) is a skin condition of unclear etiology that occurs not uncommonly in childhood. It is often classified into the acute form, pityriasis lichenoides et varioliformis acuta (PLEVA), and the chronic form, pityriasis lichenoides chronica (PLC). We performed a comprehensive review of the English-language literature using the PubMed database of all cases of childhood PL reported from 1962 to 2014 and summarized the epidemiology, clinical features, treatment options, and prognosis of this condition in children. The proposed etiologies are discussed, including its association with infectious agents, medications, and immunizations and evidence for PL as a lymphoproliferative disorder. We found an average age of PL onset of 6.5 years, with a slight (61%) male predominance. We also found that PLEVA and PLC tend to occur with equal frequency and that, in many cases, there is clinical and histopathologic overlap between the two phenotypes. When systemic therapy is indicated, we propose that oral erythromycin and narrowband ultraviolet B phototherapy should be first-line treatment options for children with PL since they have been shown to be effective and well tolerated. In most cases, PL follows a benign course with no greater risk of cutaneous T-cell lymphoma, although given the rare case reports of transformation, long-term follow-up of these patients is recommended.


Assuntos
Clindamicina/administração & dosagem , Pitiríase Liquenoide/diagnóstico , Pitiríase Liquenoide/terapia , Terapia Ultravioleta/métodos , Adolescente , Fatores Etários , Biópsia por Agulha , Criança , Terapia Combinada , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pitiríase Liquenoide/epidemiologia , Prognóstico , Medição de Risco , Índice de Gravidade de Doença , Fatores Sexuais , Resultado do Tratamento
9.
Pediatr Dent ; 36(3): 240-4, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24960392

RESUMO

PURPOSE: The purpose of this report was to review an emerging alternative treatment to pulpectomies and extractions for nonvital primary teeth called lesion sterilization and tissue repair (LSTR) and provide the results of three clinical case applications. LSTR is a noninstrumentation endodontic treatment that involves a triantibiotic mixture in a propylene glycol vehicle, which is used to disinfect root canal systems. This concept was developed by the cariology research unit of the School of Dentistry, Niigata University, Niigata, Niigata Prefecture, Japan. This article reviews the development of the technique, clinical procedures required for the technique, three clinical applications and radiographic documentation and follow-up, and a short literature review of the current evidence supporting its application in clinical practice.


Assuntos
Antibacterianos/uso terapêutico , Desinfetantes de Equipamento Odontológico/uso terapêutico , Dente Molar/efeitos dos fármacos , Abscesso Periodontal/tratamento farmacológico , Dente Decíduo/efeitos dos fármacos , Dente não Vital/tratamento farmacológico , Antibacterianos/administração & dosagem , Criança , Pré-Escolar , Ciprofloxacina/administração & dosagem , Ciprofloxacina/uso terapêutico , Clindamicina/administração & dosagem , Clindamicina/uso terapêutico , Cárie Dentária/tratamento farmacológico , Cárie Dentária/terapia , Cavidade Pulpar/efeitos dos fármacos , Necrose da Polpa Dentária/tratamento farmacológico , Combinação de Medicamentos , Feminino , Seguimentos , Defeitos da Furca/tratamento farmacológico , Humanos , Hidrocarbonetos Iodados/administração & dosagem , Hidrocarbonetos Iodados/uso terapêutico , Masculino , Metronidazol/administração & dosagem , Metronidazol/uso terapêutico , Polietilenoglicóis/administração & dosagem , Preparo de Canal Radicular/métodos
10.
J Drugs Dermatol ; 12(3): 277-82, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23545909

RESUMO

Combination therapy using medications with complementary mechanisms of action is the standard of care in treating acne. We report results of a clinical trial evaluating the use of a fixed-dose tretinoin 0.025%/clindamycin phosphate 1.2% (T/CP) gel in combination with a benzoyl peroxide 6% foaming cloth compared with T/CP alone for facial acne. At week 12, the combination therapy group showed a trend toward greater efficacy compared with T/CP alone. There was a high success rate observed in the study, which may be attributable to the large percentage of adult female acne patients enrolled. Cutaneous adverse events were not statistically different in using combination therapy compared with T/CP alone.


Assuntos
Acne Vulgar/tratamento farmacológico , Peróxido de Benzoíla/uso terapêutico , Clindamicina/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Tretinoína/uso terapêutico , Acne Vulgar/patologia , Administração Cutânea , Adolescente , Adulto , Peróxido de Benzoíla/administração & dosagem , Peróxido de Benzoíla/efeitos adversos , Clindamicina/administração & dosagem , Clindamicina/efeitos adversos , Fármacos Dermatológicos/administração & dosagem , Fármacos Dermatológicos/efeitos adversos , Combinação de Medicamentos , Quimioterapia Combinada , Face , Feminino , Géis , Humanos , Masculino , Pessoa de Meia-Idade , Método Simples-Cego , Tretinoína/administração & dosagem , Tretinoína/efeitos adversos , Adulto Jovem
11.
Antimicrob Agents Chemother ; 56(5): 2518-23, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22314534

RESUMO

Recent exposure to azoles is an important risk factor for infection with fluconazole-resistant Candida spp., but little is known about the role of antibacterial drug exposure in the emergence of drug-resistant Candida. We did a prospective nationwide surveillance study of candidemia in Israel and analyzed the propensity score-adjusted association between antifungal and antibacterial drug exposure and bloodstream infection with C. glabrata and fluconazole-resistant Candida isolates. Four hundred forty-four episodes of candidemia (450 Candida isolates, 69 [15%] C. glabrata isolates, and 38 [8.5%] fluconazole-resistant isolates) from 18 medical centers in Israel were included. C. glabrata bloodstream infection was strongly associated with recent metronidazole exposure (odds ratio [OR], 3.2; P < 0.001). Infection with a fluconazole-resistant isolate was associated with exposure to carbapenems, trimethoprim-sulfamethoxazole, clindamycin, and colistin (odds ratio, 2.8; P = 0.01). The inclusion of antibacterial drug exposure in a multivariable model significantly enhanced the model's predictive accuracy for fluconazole-resistant Candida bloodstream infection. Our findings may be relevant to the selection of empirical antifungal treatment and broaden the scope of antibiotic-associated collateral damage.


Assuntos
Antibacterianos/efeitos adversos , Infecções Bacterianas/tratamento farmacológico , Candida glabrata/efeitos dos fármacos , Candidemia/tratamento farmacológico , Candidíase/tratamento farmacológico , Fluconazol/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/administração & dosagem , Antifúngicos/administração & dosagem , Antifúngicos/uso terapêutico , Bactérias/efeitos dos fármacos , Bactérias/crescimento & desenvolvimento , Infecções Bacterianas/microbiologia , Candida glabrata/fisiologia , Candidemia/etiologia , Candidemia/microbiologia , Candidíase/etiologia , Candidíase/microbiologia , Carbapenêmicos/administração & dosagem , Carbapenêmicos/efeitos adversos , Clindamicina/administração & dosagem , Clindamicina/efeitos adversos , Coinfecção , Colistina/administração & dosagem , Colistina/efeitos adversos , Farmacorresistência Fúngica , Feminino , Fluconazol/administração & dosagem , Humanos , Israel , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Razão de Chances , Estudos Prospectivos , Fatores de Risco , Combinação Trimetoprima e Sulfametoxazol/administração & dosagem , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos
12.
Antimicrob Agents Chemother ; 56(5): 2565-9, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22354306

RESUMO

The objective of this study was to identify the oral pathogens found in odontogenic infections, to determine their susceptibilities to amoxicillin-clavulanic acid (AMC), clindamycin (CLI), doxycycline (DOX), levofloxacin (LVX), moxifloxacin (MXF), and penicillin (PEN), and to search for associations between specific pathogens and types of infection. Swabs from patients enrolled in a randomized, double-blind phase II trial comparing MXF with CLI for the treatment of odontogenic abscesses or inflammatory infiltrates were cultured on media for aerobes and anaerobes. All bacterial isolates were identified at the species level. Overall, 205 isolates were cultured from 71 patients: 77 viridans group streptococci, 56 Prevotella spp., 19 Neisseria spp., 17 Streptococcus anginosus group isolates and hemolytic streptococci, 15 other anaerobes, and 21 other bacteria. Ninety-eight percent of pathogens were susceptible to MXF, 96% to AMC, 85% to LVX, 67% to PEN, 60% to CLI, and 50% to DOX. S. anginosus group and hemolytic streptococci were found significantly more frequently (P = 0.04) in patients with abscesses (12/95) than in patients with infiltrates (5/110). In four patients with infiltrates who failed to respond to CLI therapy, three isolates of the Streptococcus mitis group and four Neisseria spp. resistant to CLI were found. In this study, S. anginosus group and hemolytic streptococci were clearly associated with odontogenic abscesses. Our analysis suggests that viridans group streptococci and Neisseria spp. play a decisive role in the etiology of odontogenic infiltrates. The high in vitro activity of MXF against odontogenic bacteria corresponds well to its clinical results in the treatment of odontogenic abscesses and infiltrates.


Assuntos
Compostos Aza/uso terapêutico , Bactérias Aeróbias/efeitos dos fármacos , Bactérias Anaeróbias/efeitos dos fármacos , Infecções Bacterianas/tratamento farmacológico , Clindamicina/uso terapêutico , Abscesso Periodontal/tratamento farmacológico , Quinolinas/uso terapêutico , Combinação Amoxicilina e Clavulanato de Potássio/administração & dosagem , Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Compostos Aza/administração & dosagem , Bactérias Aeróbias/crescimento & desenvolvimento , Bactérias Anaeróbias/crescimento & desenvolvimento , Infecções Bacterianas/microbiologia , Clindamicina/administração & dosagem , Meios de Cultura , Método Duplo-Cego , Feminino , Fluoroquinolonas , Alemanha , Humanos , Masculino , Testes de Sensibilidade Microbiana , Moxifloxacina , Pacientes Ambulatoriais , Penicilinas/administração & dosagem , Penicilinas/uso terapêutico , Abscesso Periodontal/microbiologia , Estudos Prospectivos , Quinolinas/administração & dosagem
13.
Curr Clin Pharmacol ; 7(1): 36-40, 2012 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-22082330

RESUMO

As bacterial vaginosis (BV) is a potential cause of obstetric complications and gynecological disorders, there is substantial interest in establishing the most effective treatment. Standard treatment - metronidazole or clindamycin, by either vaginal or oral route � is followed by relapses in about 30% of cases, within a month from treatment completion. This inability to prevent recurrences reflects our lack of knowledge on the origins of BV. Atopobium vaginae has been recently reported to be associated with BV in around 80% of the cases and might be involved in the therapeutic failures. This review looks at the potential benefits of nifuratel against A. vaginae compared to the standard treatments with metronidazole and clindamycin. In vitro, nifuratel is able to inhibit the growth of A. vaginae, with a MIC range of 0.125-1 µg/mL; it is active against G. vaginalis and does not affect lactobacilli. Metronidazole is active against A. vaginae only at very high concentrations (8-256 µg/mL); it is partially active against G. vaginalis and also has no effect on lactobacilli. Clindamycin acts against A. vaginae with an MIC lower than 0.125 µg/mL and is active on G. vaginalis but it also affects lactobacilli, altering the vaginal environment. These observations suggest that nifuratel is probably the most valid therapeutic agent for BV treatment.


Assuntos
Actinobacteria/efeitos dos fármacos , Nifuratel/uso terapêutico , Vaginose Bacteriana/tratamento farmacológico , Actinobacteria/isolamento & purificação , Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Clindamicina/administração & dosagem , Clindamicina/farmacologia , Clindamicina/uso terapêutico , Relação Dose-Resposta a Droga , Feminino , Gardnerella vaginalis/efeitos dos fármacos , Gardnerella vaginalis/isolamento & purificação , Humanos , Metronidazol/administração & dosagem , Metronidazol/farmacologia , Metronidazol/uso terapêutico , Testes de Sensibilidade Microbiana , Nifuratel/administração & dosagem , Nifuratel/farmacologia , Prevenção Secundária , Vaginose Bacteriana/microbiologia
14.
Lik Sprava ; (3-4): 90-6, 2012.
Artigo em Ucraniano | MEDLINE | ID: mdl-23356145

RESUMO

Character of microflora of exsudate of abdominals and mucosis microflora of vermicular appendix is studied for patients with the destructive forms of appendicitis with the purpose of development of variants of antibacterial therapy at surgical treatment of patients with acute appendicitis. The patients with the destructive forms of appendicitis, which were on treatment in a municipal clinical hospital N 4 Kyiv for period 2004-2010. An Inflammatory-destructive process in an appendix is conditioned by both aerobic (Escherichia coli - 46,6 %, Enterobacter - 4,2 %, Citrobacter - 4,2 %, Klebsiella - 3,3 %, Pseudomonas aeruginosa - 5,8 %, Staphylococcus - 4,2 %) and anaerobic microorganisms (Bacteroides - 100 %) and increase Candida - 17,5 %. Antibacterial therapy is effective at 46,7 % patients with acute appendicitis. At 49,6 % patients acute appendicitis develops on a background dysbiotic intestinal disturbances. Clinically the effective charts of empiric antibacterial monotherapy 6 days it is been: Moxifloxacini intravenously 400 mgs one time in twenty-four hours during, Ertapenemi for a 1 g one time in twenty-four hours intravenously and combined - Aztreonami for a 1 g twice in twenty-four hours and of Clindamycini for 600 mgs twice in twenty-four hours, intramuscular during; Cefepimumi for a 1 g twice in twenty-four hours and of Clindamycini for 600 mgs twice in twenty-four hours, intramuscular.


Assuntos
Antibacterianos/administração & dosagem , Apendicectomia , Apendicite/tratamento farmacológico , Apêndice/cirurgia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Apendicite/microbiologia , Apendicite/cirurgia , Apêndice/efeitos dos fármacos , Apêndice/microbiologia , Compostos Aza/administração & dosagem , Aztreonam/administração & dosagem , Bactérias Aeróbias/efeitos dos fármacos , Bactérias Aeróbias/fisiologia , Bactérias Anaeróbias/efeitos dos fármacos , Bactérias Anaeróbias/fisiologia , Candida/efeitos dos fármacos , Candida/fisiologia , Cefepima , Cefalosporinas/administração & dosagem , Clindamicina/administração & dosagem , Gerenciamento Clínico , Vias de Administração de Medicamentos , Esquema de Medicação , Ertapenem , Feminino , Fluoroquinolonas , Humanos , Masculino , Pessoa de Meia-Idade , Moxifloxacina , Quinolinas/administração & dosagem , beta-Lactamas/administração & dosagem
15.
J Plast Reconstr Aesthet Surg ; 64(12): e313-6, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21798834

RESUMO

The infection of a breast implant or tissue expander is a major complication with significant psychological and medical ramifications. The incidence has been reported to range from 1.1% in cosmetic augmentations to as high to 24% in a series of reconstructive cases. Gentamicin Surgical Implant is a surgical implant comprised of a lyophilised collagen matrix impregnated with a broad-spectrum antibiotic. When placed in the operative field, it achieves very high local concentrations of drug several fold above the minimal inhibitory concentrations; and the collagen carrier is absorbed. Its beneficial use has been reported in other fields of surgery. Gentamicin sponges were used in four cases of periprosthetic infections. The implants were removed, the pockets cleaned with pulse lavage and the implants were replaced, together with a gentamicin collagen implant. This was followed by a 6-week systemic antibiotic regimen. The patients had uneventful recovery and have not developed capsular contracture. Gentamicin collagen sponges may be used as an adjunct in the salvage of infected breast implants. Periprosthetic infections, as well as the use of gentamicin, are reviewed.


Assuntos
Antibacterianos/administração & dosagem , Implantes de Mama/efeitos adversos , Gentamicinas/administração & dosagem , Infecções Relacionadas à Prótese/tratamento farmacológico , Adulto , Ciprofloxacina/administração & dosagem , Clindamicina/administração & dosagem , Colágeno , Terapia Combinada , Feminino , Liofilização , Humanos , Pessoa de Meia-Idade , Desenho de Prótese , Infecções Relacionadas à Prótese/cirurgia , Tampões de Gaze Cirúrgicos
16.
Photodermatol Photoimmunol Photomed ; 27(3): 162-3, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21535172

RESUMO

Progressive macular hypomelanosis (PMH) is an acquired disorder of skin pigmentation, which is mostly under-diagnosed. It is characterized by nummular hypopigmented lesions appearing on the trunk in young persons. Several treatment options are available, although topical clindamycin and benzoyl peroxide have been used traditionally. However, good results have recently been achieved using narrow-band ultraviolet B (NBUVB) phototherapy. We present the case of a 13-year-old girl with hypopigmented lesions on the trunk and limbs that had progressed over 1 year and that were diagnosed as PMH. The patient was initially treated with topical clindamycin and benzoyl peroxide. However, little improvement was seen and treatment was then started with NBUVB phototherapy. After 25 sessions, with a total cumulative dose of 18 J/cm(2) , the patient showed almost total repigmentation of the lesions. The treatment of PMH is often difficult, and very little is currently known about the treatment response in this disorder, as most reports have very small series of patients with a short disease progression time. NBUVB phototherapy has been shown to be effective, as seen in our patient, although in many cases, there is recurrence after the cessation of treatment.


Assuntos
Hipopigmentação/patologia , Hipopigmentação/terapia , Terapia a Laser/métodos , Adolescente , Antibacterianos/administração & dosagem , Peróxido de Benzoíla/administração & dosagem , Clindamicina/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Feminino , Humanos , Hipopigmentação/diagnóstico
17.
J Appl Oral Sci ; 18(3): 259-63, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20857004

RESUMO

OBJECTIVE: New drugs have to be assessed in endodontic therapy due to the presence of microorganisms resistant to therapeutic procedures. Thus, this study evaluated the time- and concentration-dependent cytotoxicity of different antibiotics used in endodontic therapy. MATERIAL AND METHODS: Human gingival fibroblasts were treated and divided into the following experimental groups: Group I - control; Group II - ciprofloxacin hydrochloride; Group III - clyndamicin hydrochloride; and Group IV - metronidazole. Each drug was used at concentrations of 5, 50, 150, and 300 mg/L for 24, 48, 72, and 96 h. Cytotoxicity was evaluated by the MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and spectrophotometric reading of ELISA plates. The results were analyzed by BioEstat 4.0 software using Kruskal-Wallis and Dunn's tests at a significance level of 5%. Cell viability was assessed for the different concentrations and times. RESULTS: All drugs presented dose-dependent cytotoxicity. Concentrations of 5 and 50 mg/L produced viable fibroblasts at all experimental times in all groups. CONCLUSIONS: Cell viability at 24 h was greater than in the other experimental times. Comparison between the same concentrations of antibiotics at different times showed that metronidazole presented the highest cell viability at 72 and 96 h compared to the other antibiotics, whereas clyndamicin hydrochloride showed higher cell viability at 72 h than ciprofloxacin hydrochloride.


Assuntos
Antibacterianos/toxicidade , Fibroblastos/efeitos dos fármacos , Gengiva/efeitos dos fármacos , Tratamento do Canal Radicular , Antibacterianos/administração & dosagem , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/toxicidade , Linhagem Celular , Núcleo Celular/efeitos dos fármacos , Forma Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Ciprofloxacina/administração & dosagem , Ciprofloxacina/toxicidade , Clindamicina/administração & dosagem , Clindamicina/toxicidade , Corantes , Citoplasma/efeitos dos fármacos , Relação Dose-Resposta a Droga , Gengiva/citologia , Humanos , Metronidazol/administração & dosagem , Metronidazol/toxicidade , Espectrofotometria , Sais de Tetrazólio , Tiazóis , Fatores de Tempo
18.
J. appl. oral sci ; 18(3): 259-263, May-June 2010. ilus, tab
Artigo em Inglês | LILACS | ID: lil-557090

RESUMO

OBJECTIVE: New drugs have to be assessed in endodontic therapy due to the presence of microorganisms resistant to therapeutic procedures. Thus, this study evaluated the time- and concentration-dependent cytotoxicity of different antibiotics used in endodontic therapy. MATERIAL AND METHODS: Human gingival fibroblasts were treated and divided into the following experimental groups: Group I - control; Group II - ciprofoxacin hydrochloride; Group III - clyndamicin hydrochloride; and Group IV - metronidazole. Each drug was used at concentrations of 5, 50, 150, and 300 mg/L for 24, 48, 72, and 96 h. Cytotoxicity was evaluated by the MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and spectrophotometric reading of ELISA plates. The results were analyzed by BioEstat 4.0 software using Kruskal-Wallis and Dunn's tests at a signifcance level of 5 percent. Cell viability was assessed for the different concentrations and times. RESULTS: All drugs presented dose-dependent cytotoxicity. Concentrations of 5 and 50 mgjL produced viable fibroblasts at all experimental times in all groups. CONCLUSIONS: Cell viability at 24 h was greater than in the other experimental times. Comparison between the same concentrations of antibiotics at different times showed that metronidazole presented the highest cell viability at 72 and 96 h compared to the other antibiotics, whereas clyndamicin hydrochloride showed higher cell viability at 72 h than ciprofoxacin hydrochloride.


Assuntos
Humanos , Antibacterianos/toxicidade , Fibroblastos/efeitos dos fármacos , Gengiva/efeitos dos fármacos , Tratamento do Canal Radicular , Antibacterianos/administração & dosagem , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/toxicidade , Linhagem Celular , Núcleo Celular/efeitos dos fármacos , Forma Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Ciprofloxacina/administração & dosagem , Ciprofloxacina/toxicidade , Clindamicina/administração & dosagem , Clindamicina/toxicidade , Corantes , Citoplasma/efeitos dos fármacos , Relação Dose-Resposta a Droga , Gengiva/citologia , Metronidazol/administração & dosagem , Metronidazol/toxicidade , Espectrofotometria , Fatores de Tempo , Sais de Tetrazólio , Tiazóis
19.
Cutis ; 84(5 Suppl): 18-24, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19999189

RESUMO

This article reviews various studies supporting the use of a fixed-combination monotherapy hydrating gel containing clindamycin 1% and benzoyl peroxide 5% (C/BPO), which is the only available formulation with a hydrating gel vehicle containing a humectant and an occlusive. The C/BPO hydrating gel provides a flexible and complementary efficacy and/or tolerability profile when used alone or with topical retinoids, which results in rapid response in inflammatory and noninflammatory acne. It also mitigates the irritation associated with disease flare or topical retinoid use, and reduces the postinflammatory hyperpigmentation (PIH) seen in women and in patients with skin of color with acne. These benefits are important because they have the potential to improve patient adherence to therapy and clinical outcomes.


Assuntos
Acne Vulgar/tratamento farmacológico , Peróxido de Benzoíla/uso terapêutico , Clindamicina/uso terapêutico , Acne Vulgar/patologia , Administração Cutânea , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Antibacterianos/uso terapêutico , Peróxido de Benzoíla/administração & dosagem , Peróxido de Benzoíla/efeitos adversos , Clindamicina/administração & dosagem , Clindamicina/efeitos adversos , Fármacos Dermatológicos/administração & dosagem , Fármacos Dermatológicos/efeitos adversos , Fármacos Dermatológicos/uso terapêutico , Combinação de Medicamentos , Sinergismo Farmacológico , Excipientes/química , Géis , Humanos
20.
Cochrane Database Syst Rev ; (4): CD006289, 2009 Oct 07.
Artigo em Inglês | MEDLINE | ID: mdl-19821358

RESUMO

BACKGROUND: The dominance of lactobacilli in healthy vaginal microbiota and its depletion in bacterial vaginosis (BV) has given rise to the concept of oral or vaginal instillation of probiotic Lactobacillus strains for the management of this condition. OBJECTIVES: To ascertain the efficacy of probiotics in the treatment of BV. SEARCH STRATEGY: We searched electronic databases irrespective of publication status or language. These included: Cochrane Central Register of Controlled Trials (CENTRAL), the HIV/AIDS and STD Cochrane Review Groups' specialized registers, the Cochrane Complementary Medicine Field's Register of Controlled Trials, MEDLINE (1966 to 2008), EMBASE (1980 to 2007), ISI science citation index (1955 to 2007), CINAHL (Cumulative Index to Nursing & Allied Health Literature (1982 to 2007).We handsearched of specialty journals, conference proceedings and publications list on the website of the International Scientific Association of Probiotics and Prebiotics (http://www.isapp.net/default.asp).For unpublished studies or ongoing trials, we contacted authors from relevant publications, nutraceutical companies and probiotic-related scientific associations. We searched electronic databases on ongoing clinical trials. SELECTION CRITERIA: Randomized controlled trials using probiotics for the treatment of women of any age diagnosed with bacterial vaginosis, regardless of diagnostic method used. The probiotic preparation could be single or "cocktail" of strains, any preparation type/dosage/route of administration. Studies comparing probiotics with placebo, probiotics used in conjunction with conventional antibiotics compared with placebo or probiotics alone compared with conventional antibiotics were eligible for inclusion. DATA COLLECTION AND ANALYSIS: We screened titles and abstracts , obtained full reports of relevant trialsand independently appraised them for eligibility. A data extraction form was used to extract data from the four included studies. For dichotomous outcomes, odds ratios (OR) and 95% confidence intervals (CI) were derived for each study using RevMan (versions 4.2 and 5). We did not perform meta-analysis due to significant differences in the probiotic preparations and trial methodologies. MAIN RESULTS: Analysis suggests beneficial outcome of microbiological cure with the oral metronidazole/probiotic regimen (OR 0.09 (95% CI 0.03 to 0.26)) and the probiotic/estriol preparation (OR 0.02, (95% CI 0.00 to 0.47)). For the probiotic/estriol preparation, the OR and 95% CI for physician-reported resolution of symptoms was OR 0.04 (95% CI 0.00 to 0.56). AUTHORS' CONCLUSIONS: The results do not provide sufficient evidence for or against recommending probiotics for the treatment of BV. The metronidazole/probiotic regimen and probiotic/estriol perparation appear promising but well-designed randomized controlled trials with standardized methodologies and larger patient size are needed.


Assuntos
Lactobacillus , Probióticos/administração & dosagem , Vaginose Bacteriana/terapia , Antibacterianos/administração & dosagem , Clindamicina/administração & dosagem , Estriol/administração & dosagem , Feminino , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Vagina/microbiologia , Vaginose Bacteriana/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA